Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12474021 | 0.92 | L3MBTL1 (0.43) | L3MBTL1MAPTLMNAATMRAB9A | |
| SCHEMBL622815 | 0.85 | SYK (0.42) | F10ALOX5APFEN1HTR2ASLC6A4 | |
| SCHEMBL623063 | 0.85 | MKNK1 (0.47) | MAPTATMSCN9ATOP1NTRK1 | |
| SCHEMBL623788 | 0.81 | TNK2 (0.51) | MAPTMKNK1MKNK2 | |
| SCHEMBL624679 | 0.81 | SMN1; SMN2 (0.56) | RAB9AMKNK1MKNK2 | |
| SCHEMBL12474044 | 0.80 | MKNK1 (0.44) | MAPTRAB9AMKNK1MKNK2 | |
| SCHEMBL12474033 | 0.80 | DRD1 (0.41) | MAPTATMSCN9AMKNK1MKNK2 | |
| SCHEMBL29888283 | 0.79 | MKNK1 (0.54) | SCN9ATOP1MKNK1MKNK2 | |
| SCHEMBL12474040 | 0.78 | LTA4H (0.43) | MAPTATMSCN9AALOX5APFEN1 | |
| SCHEMBL31291514 | 0.78 | LTA4H (0.43) | MAPTATMSCN9AALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-11279713-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-22 | — | — | US | disclosed |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10654874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| EP-2603513-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF AS AMPA RECEPTOR POSITIVE ALLOSTERIC MODULATOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9884875-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9499568-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150073137-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-03-12 | — | — | US | disclosed |
| US-8916551-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8778934-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8575154-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2603513-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| WO-2012020848-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080817-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20190263832-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20130190291-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20200317692-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20180162875-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-10654874-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-11279713-B2 | Heterocyclic compound and use thereof | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20130184266-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20150073137-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20170022222-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
| US-20120077799-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | L3MBTL1 4639/4885MAPT 277/4885LMNA 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.